Bio-Path (NASDAQ:BPTH) Price Target Raised to $40.00 at Roth Mkm

Bio-Path (NASDAQ:BPTH) had its price target lifted by Roth Mkm from $12.00 to $40.00 in a research note released on Wednesday morning, Benzinga reports. They currently have a buy rating on the stock.

Separately, StockNews.com assumed coverage on Bio-Path in a research note on Saturday, March 23rd. They set a sell rating on the stock.

Bio-Path Stock Performance

Bio-Path stock opened at $4.04 on Wednesday. The business’s 50-day simple moving average is $7.08 and its 200-day simple moving average is $8.97. The firm has a market capitalization of $2.75 million, a PE ratio of -0.10 and a beta of 0.66. Bio-Path has a 52 week low of $3.51 and a 52 week high of $44.80.

Bio-Path (NASDAQ:BPTH) last posted its quarterly earnings data on Friday, March 8th. The company reported ($5.40) EPS for the quarter, hitting analysts’ consensus estimates of ($5.40). During the same period in the prior year, the business earned ($10.60) earnings per share. Research analysts forecast that Bio-Path will post -20.8 earnings per share for the current year.

Institutional Investors Weigh In On Bio-Path

Several large investors have recently modified their holdings of the stock. Vanguard Group Inc. grew its stake in shares of Bio-Path by 77.5% in the 4th quarter. Vanguard Group Inc. now owns 270,029 shares of the company’s stock valued at $125,000 after purchasing an additional 117,914 shares during the period. Walleye Capital LLC bought a new stake in shares of Bio-Path in the 3rd quarter valued at approximately $77,000. Renaissance Technologies LLC bought a new stake in shares of Bio-Path in the 2nd quarter valued at approximately $70,000. Citadel Advisors LLC bought a new stake in shares of Bio-Path in the 3rd quarter valued at approximately $35,000. Finally, Virtu Financial LLC bought a new stake in shares of Bio-Path in the 1st quarter valued at approximately $38,000. 5.74% of the stock is currently owned by institutional investors.

Bio-Path Company Profile

Bio-Path Holdings, Inc operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction.